EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMixed-Methods-StudieOpen Access · CC BY 4.0

Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study

Abhishek Abhishek iD, Christopher Carroll iD, Munira Essat iD, Jo Leaviss iD, Georgina Nakafero iD, Amy Fuller iD, Matthew J Grainge iD, Jennie Hancox iD, Hywel C Williams iD, Timothy Card iD, Maarten W Taal iD, Guruprasad P Aithal iD und 6 weitere

Health Technology Assessment · 2026

DOI: 10.3310/plrf8845 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2026. Verfasst von Abhishek Abhishek und 17 weiteren Autor:innen. Beteiligte Einrichtung: Academic Rheumatology, University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Drug Monitoring, Hematologic Tests, Immunosuppressive Agents. Die Arbeit nennt 385 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal monitoring strategy for adults with inflammatory conditions established on immune-suppressing treatment is unknown.

Objectives

To ascertain the optimum strategy of monitoring blood tests for patients established on immune-suppressing drugs. The objectives were to: investigate the association between different strategies of monitoring and detection of pre-specified haematological, hepatic or renal side effects identify prognostic factors associated with pre-specified haematological, hepatic or renal side effects develop prediction models for pre-specified haematological, hepatic or renal side effects evaluate cost-effectiveness of testing strategies, and explore patients’ and clinicians’ experiences of current testing strategies, and acceptability of recommended strategies.

Design

The study undertook systematic review, prognostic modelling, health economic modelling of alternate monitoring intervals, and qualitative study.

Setting

Primary and secondary care.

Participants

Data from the UK’s Clinical Practice Research Datalink and British Association of Dermatologists Biologics Register were used for prediction modelling. Patients with inflammatory conditions treated with immune-suppressing drugs and health professionals were interviewed.

Results

There were differences in testing strategies used, outcome definitions and follow-up precluding evidence synthesis. However, clinically significant pre-specified side effects were found to be uncommon or very uncommon during long-term treatment. There was high-quality evidence for elevated liver enzymes and folate non-supplementation being prognostic for methotrexate hepatotoxicity, mercaptopurine being prognostic for thiopurine hepatotoxicity and myelotoxicity; poor thiopurine metabolizer being prognostic for cytopenia; and elevated liver enzymes being prognostic for hepatotoxicity due to anti-tumour necrosis factor-alpha. Five prediction models were developed and validated. They had excellent performance characteristics. The calibration slope (95% confidence interval) in validation cohort was 0.94 (0.85 to 1.02) for methotrexate, 1.10 (0.84 to 1.36) for thiopurines, 0.91 (0.74 to 1.07) for leflunomide, 1.19 (0.96 to 1.43) for sulfasalazine, and 0.90 (0.61 to 1.19) for 5-aminosalicylates. Prediction modelling could not be undertaken for anti-tumour necrosis factor-alpha and mycophenolate due to few outcomes. Health economic modelling found it was cost-effective to increase the interval between monitoring blood tests except in very high-risk scenarios for some drugs (e.g. biennial testing in leflunomide). Eighteen patients from a range of risk profiles, and 13 health professionals were interviewed remotely. They found it acceptable to increase the interval between monitoring blood tests from 3-monthly to 6-monthly or annually depending on their risk profiles.

Limitations

It was not possible to synthesise the association between different strategies of testing and detection of pre-specified side effects. A meta-analysis of prognostic factors was not possible.

Conclusions

Clinically significant myelotoxicity, hepatotoxicity and nephrotoxicity are uncommon during long-term immune-suppressing drug treatment and were predicted using readily available information. Extending the intervals between monitoring blood tests was more cost-effective than the current practice. It was acceptable to patients and health professionals to increase the interval between monitoring blood tests. Future work Test clinical effectiveness, undertake knowledge mobilisation, validate in non-UK populations. Research on other biologics. Study registration The study is registered as PROSPERO CRD42020208042, CRD42020208042 and the interview studies were registered on ClinicalTrials.gov NCT05458531. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR130580) and is published in full in Health Technology Assessment ; Vol. 30, No. 64. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringHematologic TestsImmunosuppressive AgentsAdultAgedFemaleHumansMaleMiddle AgedCost-Benefit AnalysisCost-Effectiveness AnalysisMercaptopurineMethotrexateModels, EconomicUnited Kingdom

Stichwörter der Autor:innen

5-AMINOSALICYLATEANTI-TNF-ALPHADRUG TOXICITYLEFLUNOMIDEMETHOTREXATEMONITORINGSULFASALAZINETHIOPURINE

Substanzen

Immunosuppressive AgentsMercaptopurineMethotrexate

Autor:innen und Institutionen

  • Academic Rheumatology, University of Nottingham, Nottingham, UK.
  • School of Health and Related Research, University of Sheffield, Sheffield, UK.
  • Lifespan and Population Health, University of Nottingham, Nottingham, UK.
  • School of Health Sciences, Loughborough University, Loughborough, UK.
  • Centre for Kidney Research and Innovation, Translational Medical Sciences, University of Nottingham, Derby, UK.
  • Nottingham Digestive Diseases Centre, Translational Medical Sciences, University of Nottingham, Nottingham, UK.

ORCID-Profile: Abhishek Abhishek, Christopher Carroll, Munira Essat, Jo Leaviss, Georgina Nakafero, Amy Fuller, Matthew J Grainge, Jennie Hancox, Hywel C Williams, Timothy Card, Maarten W Taal, Guruprasad P Aithal, Christopher P Fox, Christian D Mallen, Kavita Vedhara, Danielle A van der Windt, Matthew D Stevenson, Richard D Riley

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Abhishek, A., Carroll, C., Essat, M., Leaviss, J., Nakafero, G., Fuller, A., Grainge, M. J., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Vedhara, K., van der Windt, D. A., Stevenson, M. D., & Riley, R. D. (2026). Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study. Health Technology Assessment. https://doi.org/10.3310/plrf8845

Vancouver

Abhishek A, Carroll C, Essat M, Leaviss J, Nakafero G, Fuller A, et al. Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study. Health Technology Assessment. 2026. doi:10.3310/plrf8845

BibTeX
@article{Abhishek2026,
  author = {Abhishek, Abhishek and Carroll, Christopher and Essat, Munira and Leaviss, Jo and Nakafero, Georgina and Fuller, Amy and Grainge, Matthew J and Hancox, Jennie and Williams, Hywel C and Card, Timothy and Taal, Maarten W and Aithal, Guruprasad P and Fox, Christopher P and Mallen, Christian D and Vedhara, Kavita and van der Windt, Danielle A and Stevenson, Matthew D and Riley, Richard D},
  title = {Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study},
  journal = {Health Technology Assessment},
  year = {2026},
  doi = {10.3310/plrf8845}
}
Kostenlos starten →